Department of Neurology, Philipps-University, Marburg, Germany.
J Alzheimers Dis. 2010;20(1):135-43. doi: 10.3233/JAD-2010-1353.
Intravenous immunoglobulins (IVIG) are currently used for therapeutic purposes in autoimmune disorders. Recently, we demonstrated the presence of naturally occurring antibodies against amyloid-beta (nAbs-Abeta) within the pool of IVIG. In this study, we compared different brands of IVIG for nAbs-Abeta and have found differences in the specificity of the nAbs-Abeta towards Abeta(1-40) and Abeta(1-42). We analyzed the influence of a pH-shift over the course of antibody storage using ELISA and investigated antibody dimerization at acidic and neutral pH as well as differences in the IgG subclass distributions among the IVIG using both HPLC and a nephelometric assay. Furthermore, we investigated the epitope region of purified nAbs-Abeta. The differences found in Abeta specificity are not directly proportionate to the binding nature of these antibodies when administered in vivo. This information, however, may serve as a guide when choosing the commercial source of IVIG for therapeutic applications in Alzheimer's disease.
静脉注射用免疫球蛋白（IVIG）目前在自身免疫性疾病的治疗中使用。最近，我们在 IVIG 中发现了针对淀粉样蛋白-β（nAbs-Aβ）的天然存在的抗体。在这项研究中，我们比较了不同品牌的 IVIG 中 nAbs-Aβ的特性，并发现 nAbs-Aβ 对 Abeta（1-40）和 Abeta（1-42）的特异性存在差异。我们使用 ELISA 分析了在抗体储存过程中 pH 变化的影响，并研究了在酸性和中性 pH 下抗体二聚化的情况以及使用 HPLC 和比浊计测定的 IVIG 中 IgG 亚类分布的差异。此外，我们还研究了纯化 nAbs-Aβ 的表位区域。当这些抗体在体内给药时，发现 Abeta 特异性的差异与这些抗体的结合性质不成比例。然而，当选择用于治疗阿尔茨海默病的 IVIG 的商业来源时，这些信息可能会作为指导。
